Release date: 2018-01-24 According to the recent news of the British "Nature" magazine website and the US "MIT Technology Review" website, the University of Pennsylvania is currently preparing for the final stage of the human clinical trial of anti-cancer for CRISPR gene editing technology, and the project is about to be fully launched. This is the first attempt to treat cancer in the United States using CRISPR, marking the beginning of a new era in cancer treatment and a biomedical competition between China and the United States. The use of CRISPR gene editing technology to treat cancer is considered a revolutionary cancer therapy. The project has recently been published on the National Institutes of Health (NIH) Clinical Trial Information Network, and the details of the trial are also described in detail. This clinical trial is mainly for multiple myeloma, synovial sarcoma and mucinous liposarcoma and melanoma patients. According to the type of disease, it is divided into three groups at the same time. It is planned to recruit 18 patients over 18 years old. The phase I trial period is 5 years. The team will monitor the percentage of patients who achieved remission within 6 months, survival rate and other indicators. By then, researchers from the University of Pennsylvania will genetically modify human immune cells (T cells) to become a "weapon" to actively attack cells, identify and destroy tumor cells. The research work must first be carried out in vitro. The CRISPR technology is used to edit several key genes in T cells, making them the "ultimate nemesis" of cancer cells, then culturing, proliferating in the laboratory, and finally injecting them back into patients. To achieve the best therapeutic effect. The progress of this project in the United States also marks the beginning of bio-medical competition between China and the United States. As early as October 2016, the medical team of Sichuan University has launched the first human genetic editing clinical trial to extract immune cells. After editing, cultivating and reinjecting patients into the body, Phase I trials also focus on patient safety and survival. Carl Jon, a pioneer in immunotherapy at the University of Pennsylvania, said that this is a "competitive battle" between the most advanced biomedical sciences in China and the United States. It is very important because this kind of benign competition will eventually lead to a significant increase in technology. Source: Technology Daily Cleaned Squid Tubes,Frozen Squid Tube,Frozen Cleaned Squid Tubes,Stuffed squid tubes ZHOUSHAN JING YUAN FOOD CO.,LTD , https://www.genho-food.com